Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Carboplatin 1174Cisplatin 891Pemetrexed 847pembrolizumab 626Paclitaxel 609Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 264Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
enoxaparin sodium × Thoracic × Clear all
NCT00916669 2013-05-08

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Massachusetts General Hospital

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡